Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01935089 | Pilot Peg-Interferon-a2b in Decreasing Viral DNA in HIV | PHASE2 | COMPLETED | 20 | — | — | Aug 7, 2013 | May 2, 2016 | Jul 6, 2023 | 3 | United States |
Difference in copies of HIV DNA per CD4+ T cell between baseline and week 24, assessed by Alu-HIVgag polymerase chain reaction
| Arm | Type | Description |
|---|---|---|
| Interferon alpha | EXPERIMENTAL | pegylated Interferon alpha 2b (Pegintron) 1 µg/kg per week, 20 weeks |
| Name | Type | Description |
|---|---|---|
| Pegylated Interferon alpha 2b | DRUG | 1µg/kg/week |
Inclusion Criteria: * 18-65 years of age * Body weight between 125 and 299 lbs * Confirmed diagnosis of HIV-1 infection by western blot or by a documented HIV-1 viral load * Currently receiving ART and on ART for \> 1 year * VL \< 50 copies/ml for ≥ 1 year, with at least 2 measurements in the previ...